Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SUPN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSupernus triggers $33.4M CVR milestone payment after achieving Milestone 1
Filed May 20, 2026 · Period ending May 17, 2026 · ~1 min read
Key Changes
-
high
Company achieved Milestone 1 on March 18, 2026, triggering obligation to pay $0.50 per CVR to holders, totaling approximately $33.4 million in cash. Payment due within 20 business days of May 17, 2026 notice.
Item 2.03 — Creation of a Direct Financial Obligation verify on EDGAR → -
low
CVR Agreement was established July 30, 2025 with Equiniti Trust Company as Rights Agent, likely in connection with a prior transaction. This filing references previously disclosed agreement terms.
Item 9.01 — Financial Statements and Exhibits verify on EDGAR →
Summary
Supernus Pharmaceuticals disclosed that it achieved Milestone 1 under a Contingent Value Rights Agreement on March 18, 2026, triggering a $33.4 million cash payment obligation to CVR holders. The company notified the Rights Agent on May 17, 2026 and must deposit the funds within 20 business days. The payment represents $0.50 per CVR and is subject to applicable withholding taxes.
The CVR Agreement was originally established in July 2025 with Equiniti Trust Company as Rights Agent, likely as part of a prior corporate transaction. For retail investors, this represents a near-term cash outflow of $33.4 million that will impact the company's balance sheet. The achievement of Milestone 1 suggests the company met a specific operational or regulatory target tied to the original CVR terms. Investors should review the July 2025 CVR Agreement to understand what remaining milestones, if any, could trigger additional payment obligations.
Section-by-Section Diff
Event · Item 9.01 — Financial Statements and Exhibits
Supernus filed an 8-K listing previously filed exhibits, including a Contingent Value Rights Agreement from July 2025.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Contingent Value Rights Agreement, dated as of July 30, 2025, by and among Supernus Pharmaceuticals, Inc. and Equiniti Trust Company, LLC (incorporated by reference to Exhibit 10.1 to the Company’s Form 8-K filed on July 31, 2026, File No. 001-35518).
The filing references a Contingent Value Rights Agreement dated July 30, 2025, between Supernus and Equiniti Trust Company. This agreement was previously disclosed in a July 31, 2026 8-K. The current filing provides no new information about the CVR terms or triggering events.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 19, 2026 · How we verify